论文部分内容阅读
卫生部《新药审批办法》颁布后,至今我省研究并已上报卫生厅的新药127个,其中转报卫生部并已批准投产42个,批准临床研究21个,待审批23个,省批准临床研究16个,批准投产保健药品25个。成为全国新药研制审批品种数较多省份之一。但也有人认为:研制新药投资大,周期长,担风险不敢尝试。事实证明,新药研制并不是“高不可攀”。如:生产西药为主的“广州光华制药厂”已批准新药五个,还有生产中药的“广州奇星药厂”已批准新药四个,他们尝到了甜头,研制新药的劲头更大,现在尚有几个新项目正在研究中。
Since the promulgation of the Measures for the Examination and Approval of New Drugs by the Ministry of Health, up to now, 127 new drugs have been reported and reported to the Ministry of Health by the Ministry of Health, of which 42 were approved and put into operation, 21 were approved for clinical research, 23 were pending examination, Study 16, approved the commissioning of health care products 25. It has become one of the provinces where the examination and approval of new drug varieties is more in the province. However, some people think that: the development of new drug investment, long cycle, take the risk not try. Facts have proved that the development of new drugs is not “unattainable.” For example, “Guangzhou Guanghua Pharmaceutical Factory”, which produces mainly western medicine, has approved five new drugs and “Guangzhou Qi Xing Pharmaceutical Factory,” which produces Chinese medicine, has approved four new drugs. They have tasted the sweetness and are now more energetic in developing new drugs. Now Several new projects are still under study.